Structural Analysis of the SARS-CoV-2 Omicron Variant Proteins
Citations Over TimeTop 10% of 2021 papers
Abstract
The spread of the latest SARS-CoV-2 variant Omicron is particularly concerning because of the large number of mutations present in its genome and lack of knowledge about how these mutations would affect the current SARS-CoV-2 vaccines and treatments. Here, by performing phylogenetic analysis using the Omicron spike (S) protein sequence, we found that the Omicron S protein presented the longest evolutionary distance in relation to the other SARS-CoV-2 variants. We predicted the structures of S, M, and N proteins of the Omicron variant using AlphaFold2 and investigated how the mutations have affected the S protein and its parts, S1 NTD and RBD, in detail. We found many amino acids on RBD were mutated, which may influence the interactions between the RBD and ACE2, while also showing the S309 antibody could still be capable of neutralizing Omicron RBD. The Omicron S1 NTD structures display significant differences from the original strain, which could lead to reduced recognition by antibodies resulting in potential immune escape and decreased effectiveness of the existing vaccines. However, this study of the Omicron variant was mainly limited to structural predictions, and these findings should be explored and verified by subsequent experiments. This study provided basic data of the Omicron protein structures that lay the groundwork for future studies related to the SARS-CoV-2 Omicron variant.
Related Papers
- → ПОПУЛЯЦИОННЫЙ ИММУНИТЕТ К ВИРУСУ SARS-CoV-2 СРЕДИ НАСЕЛЕНИЯ САНКТ-ПЕТЕРБУРГА В АКТИВНУЮ ФАЗУ ЭПИДЕМИИ COVID-19(2020)12 cited
- → ОПЫТ ОЦЕНКИ ПОПУЛЯЦИОНОГО ИММУНИТЕТА К SARS-CoV-2 СРЕДИ НАСЕЛЕНИЯ ЛЕНИНГРАДСКОЙ ОБЛАСТИ В ПЕРИОД ЭПИДЕМИИ COVID-19(2020)7 cited
- → Перинатальные последствия COVID-19 (SARS-CoV-2): обзор литературы (часть I)(2022)3 cited
- → ОПЫТ ИССЛЕДОВАНИЯ СЕРОПРЕВАЛЕНТНОСТИ К ВИРУСУ SARS-CoV-2 НАСЕЛЕНИЯ ИРКУТСКОЙ ОБЛАСТИ В ПЕРИОД ВСПЫШКИ COVID-19(2020)2 cited
- → Особенности сахароснижающей фармакотерапии у пациентов с SARS-CoV-2 (COVID-19)(2021)